Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide

Figure 4

(a) Kaplan-Meier plots showing postprogression survival (PPS), according to the type of relapse. Refractory relapse, median = 3.3 months; sensitive relapse, median = 10.0 months. (b) Kaplan-Meier plots showing postprogression survival (PPS), according to the number of regimens after progression. No further regimen, median = 0.8 months; 1 regimen, median = 4.8 months; ≥2 regimens, median = 9.5 months.

(a)

(b)